These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3092 related articles for article (PubMed ID: 27079802)

  • 1. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
    Topalian SL; Taube JM; Anders RA; Pardoll DM
    Nat Rev Cancer; 2016 May; 16(5):275-87. PubMed ID: 27079802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination cancer immunotherapy and new immunomodulatory targets.
    Mahoney KM; Rennert PD; Freeman GJ
    Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint blockade in lymphoid malignancies.
    Thanarajasingam G; Thanarajasingam U; Ansell SM
    FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection.
    El Khatib MM; Sakuma T; Tonne JM; Mohamed MS; Holditch SJ; Lu B; Kudva YC; Ikeda Y
    Gene Ther; 2015 May; 22(5):430-8. PubMed ID: 25786871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.
    Diesendruck Y; Benhar I
    Drug Resist Updat; 2017 Jan; 30():39-47. PubMed ID: 28363334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
    Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
    Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    Day D; Hansen AR
    BioDrugs; 2016 Dec; 30(6):571-584. PubMed ID: 27848165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
    Howell M; Lee R; Bowyer S; Fusi A; Lorigan P
    Lung Cancer; 2015 May; 88(2):117-23. PubMed ID: 25776466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
    Buchbinder E; Hodi FS
    J Clin Invest; 2015 Sep; 125(9):3377-83. PubMed ID: 26325034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
    Koster BD; de Gruijl TD; van den Eertwegh AJ
    Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.
    Kourie HR; Awada G; Awada A
    Immunotherapy; 2017 Jun; 9(8):647-657. PubMed ID: 28653570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Advanced Lung Cancer.
    Asmar R; Rizvi NA
    Cancer J; 2015; 21(5):383-91. PubMed ID: 26389763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 155.